Ferriprox

FDA Approves New Formulation for Ferriprox (Deferiprone) Twice-a-Day Tablets
Clinical News

FDA Approves New Formulation for Ferriprox (Deferiprone) Twice-a-Day Tablets

Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., today announced that the U.S. Food and Drug Administration (FDA) has approved Ferriprox® (deferiprone) twice-a-day tablets for the treatment…
Back to top button